Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TACT
TACT logo

TACT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy TransAct Technologies Inc (TACT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.280
1 Day change
0.31%
52 Week Range
5.700
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

TransAct Technologies Inc (TACT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral to bearish, options data shows no significant trading sentiment, and financial performance is weak with declining net income and EPS. Without any positive catalysts or strong trading signals, holding off on this investment is advisable.

Technical Analysis

The technical indicators for TACT are mixed to bearish. The MACD is slightly positive but contracting, RSI is neutral at 39.59, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at $3.123, and resistance is at $3.597. The stock is trading below its pivot point of $3.36, indicating weakness.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
2

Positive Catalysts

  • NULL identified. No recent news, no significant insider or hedge fund activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • Weak financial performance in Q4 2025 with a significant drop in net income (-85.79% YoY) and EPS (-86.08% YoY). The stock also has bearish moving averages and lacks any positive trading signals.

Financial Performance

In Q4 2025, revenue increased by 11.94% YoY to $11.45M, but net income dropped significantly by 85.79% YoY to -$1.13M. EPS also fell by 86.08% YoY to -$0.11. Gross margin improved to 47.57%, up 7.65% YoY, but overall profitability remains a concern.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is available for TACT.

Wall Street analysts forecast TACT stock price to rise
1 Analyst Rating
Wall Street analysts forecast TACT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.280
sliders
Low
5
Averages
5
High
5
Current: 3.280
sliders
Low
5
Averages
5
High
5
Roth Capital
Jeff Martin
Buy
downgrade
$6 -> $5
AI Analysis
2025-05-14
Reason
Roth Capital
Jeff Martin
Price Target
$6 -> $5
AI Analysis
2025-05-14
downgrade
Buy
Reason
Roth Capital analyst Jeff Martin lowered the firm's price target on TransAct Technologies to $5 from $6 and keeps a Buy rating on the shares. The firm notes that its prior thesis was based, in part, on a positive outcome from the strategic business review, which has now been suspended. FST and Casino & Gaming segments are performing well while the outlook for TransAct in 2025 remains breakeven to modestly negative on an adjusted EBITDA basis, the analyst tells investors in a research note.

People Also Watch